Oncology products achieved operational sales growth of 16.1% as compared to the same period a year ago
Contributors to the growth were: DARZALEX driven by strong share gains and market growth, CARVYKTI driven by continued share gains and site expansion, TECVAYLI driven by launch uptake and share gains from the U.S. TECVAYLI + DARZALEX FASPRO approval, TALVEY driven by share gains from expansion in the community setting, RYBREVANT/LAZCLUZE driven by launch uptake and share gains
In the fiscal six months of 2026, the negative impact of the STELARA sales decline, due to biosimilar competition, on worldwide operational sales was approximately 5.0%
Worldwide sales were $49.4 billion, a total increase of 8.2%, including an operational increase of 6.0%
no findingread · nothing bore on it
It held on this filing. No finding was written because nothing in it bore on the reason — the sentences it was read against are below.